0000950170-23-063925.txt : 20231114 0000950170-23-063925.hdr.sgml : 20231114 20231114192251 ACCESSION NUMBER: 0000950170-23-063925 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20231110 FILED AS OF DATE: 20231114 DATE AS OF CHANGE: 20231114 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Awad Antoine CENTRAL INDEX KEY: 0001820122 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37566 FILM NUMBER: 231408620 MAIL ADDRESS: STREET 1: C/O SYNLOGIC, INC. STREET 2: 301 BINNEY STREET, SUITE 402 CITY: CAMBRIDGE STATE: MA ZIP: 02142 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: SYNLOGIC, INC. CENTRAL INDEX KEY: 0001527599 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 261824804 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 301 BINNEY STREET STREET 2: SUITE 402 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-401-9975 MAIL ADDRESS: STREET 1: 301 BINNEY STREET STREET 2: SUITE 402 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Mirna Therapeutics, Inc. DATE OF NAME CHANGE: 20110809 4 1 ownership.xml 4 X0508 4 2023-11-10 0001527599 SYNLOGIC, INC. SYBX 0001820122 Awad Antoine C/O SYNLOGIC, INC. 301 BINNEY STREET, SUITE 402 CAMBRIDGE MA 02142 true Chief Operating Officer false Stock Option (right to buy) 130.35 2023-11-10 4 D false 3666 D 2029-02-28 Common Stock 3666 0 D Stock Option (right to buy) 128.85 2023-11-10 4 D false 666 D 2029-03-05 Common Stock 666 0 D Stock Option (right to buy) 9.30 2023-11-10 4 D false 6666 D 2033-03-16 Common Stock 6666 0 D Stock Option (right to buy) 25.50 2023-11-10 4 D false 4666 D 2030-03-10 Common Stock 4666 0 D Stock Option (right to buy) 27.75 2023-11-10 4 D false 4666 D 2030-07-14 Common Stock 4666 0 D Stock Option (right to buy) 52.50 2023-11-10 4 D false 4666 D 2031-03-10 Common Stock 4666 0 D Stock Option (right to buy) 29.25 2023-11-10 4 D false 11031 D 2032-02-04 Common Stock 11031 0 D Stock Option (right to buy) 9.30 2023-11-10 4 D false 16666 D 2033-03-16 Common Stock 16666 0 D Stock Option (right to buy) 1.85 2023-11-10 4 A false 3666 A 2029-02-28 Common Stock 3666 3666 D Stock Option (right to buy) 1.85 2023-11-10 4 A false 666 A 2029-03-05 Common Stock 666 666 D Stock Option (right to buy) 1.85 2023-11-10 4 A false 6666 A 2033-03-16 Common Stock 6666 6666 D Stock Option (right to buy) 1.85 2023-11-10 4 A false 4666 A 2030-03-10 Common Stock 4666 4666 D Stock Option (right to buy) 1.85 2023-11-10 4 A false 4666 A 2030-07-14 Common Stock 4666 4666 D Stock Option (right to buy) 1.85 2023-11-10 4 A false 4666 A 2031-03-10 Common Stock 4666 4666 D Stock Option (right to buy) 1.85 2023-11-10 4 A false 11031 A 2032-02-04 Common Stock 11031 11031 D Stock Option (right to buy) 1.85 2023-11-10 4 A false 16666 A 2033-03-16 Common Stock 16666 16666 D In accordance with the terms of the Synlogic, Inc. 2015 Equity Incentive Award Plan and the Company's 2017 Stock Incentive Plan (together the "Plans"), the Board of Directors of Synlogic, Inc. approved a stock option repricing pursuant to which option awards granted under the Plans were amended to reduce the exercise price to $1.85 per share, the closing stock price of the Company's Common Stock on November 10, 2023. Except for the modified exercise price, all other terms and conditions of each of the option awards will continue as set forth in the Plan and the applicable award agreements. The shares subject to this option are fully vested as of the date hereof. These performance-based stock options, granted on March 16, 2023, vest when the achievement of certain clinical and regulatory development milestones are met. The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2020 through April 1, 2024. The shares subject to this option vest in approximately equal monthly installments beginning on July 1, 2020 through July 1, 2024. The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2021 through April 1, 2025. The shares subject to this option vest in approximately equal monthly installments beginning on February 4, 2022 through February 4, 2026. The shares subject to this option vest in approximately equal monthly installments beginning on April 1, 2023 through April 1, 2027. /s/ Antoine Awad 2023-11-14